Abstract: Objective: To evaluate the clinical value of different prostate biopsy modes for the diagnosis of prostate cancer. Methods: Analyzed the clinical data of 355 cases that underwent prostate biopsy. 110 cases (group A) received transrectal prostate biopsy. 144 cases (group B) received 12-core transperineal prostate biopsy and 101 cases (group C) received 24-core transperineal prostate biopsy. Compare the positive rates and complication rates of three groups in different PSA levels. Results: The positive rate of biopsy with PSA<10.0ng/ml in group C was 32.3%, which was higher than that of group A (10.8%) and group B (13.0%). The positive rates of biopsy with PSA10.0-60.0ng/ml or PSA>60.0ng/ml of the three groups had no statistics significance. The complication rates of gross hematuria, fever, bloody stool in group A were significantly higher than that in group B and group C. Group A had advantages in operating time, hospitalization time and cost (P<0．05). Conclusions: The ideal method for the diagnosis of prostate cancer is the TRUS guided 24-core transperineal prostate biopsy, which has high diagnostic accuracy, safety and fewer complications.